薬理疫学(第4版)<br>Pharmacoepidemiology (4TH)

  • ポイントキャンペーン

薬理疫学(第4版)
Pharmacoepidemiology (4TH)

  • ただいまウェブストアではご注文を受け付けておりません。 ⇒古書を探す
  • 製本 Hardcover:ハードカバー版/ページ数 889 p.
  • 言語 ENG
  • 商品コード 9780470866818
  • DDC分類 615.7042

基本説明

Continues both to reflect the increased maturation of pharmacoepedemiology and to help shape it's direction.

Table of Contents

        List of Contributors                       ix
Preface xv
Acknowledgments xix
PART I INTRODUCTION 1 (66)
What is Pharmacoepidemiology? 3 (14)
Brian L. Strom
Study Designs Available for 17 (12)
Pharmacoepidemiology Studies
Brian L. Strom
Sample Size Considerations for 29 (8)
Pharmacoepidemiology Studies
Brian L. Strom
Basic Principles of Clinical Pharmacology 37 (22)
Relevant to Pharmacoepidemiology Studies
David A. Henry
Patricia McGettigan
Anne Tonkin
Sean Hennessy
When Should One Perform 59 (8)
Pharmacoepidemiology Studies?
Brian L. Strom
PART II PERSPECTIVES ON PHARMACOEPIDEMIOLOGY 67 (64)
A View from Academia 69 (8)
Robert M. Califf
Leanne K. Madre
A View from Industry 77 (26)
Robert F. Reynolds
Dale B. Glasser
Gretchen S. Dieck
A View from Regulatory Agencies 103(28)
Peter Arlett
Jane Moseley
Paul J. Seligman
PART III SOURCES OF DATA FOR 131(2)
PHARMACOEPIDEMIOLOGY STUDIES
PART IIIa Ad Hoc Data Sources Available for 133(84)
Pharmacoepidemiology Studies
Spontaneous Reporting in the United States 135(26)
Syed Rizwanuddin Ahmad
Roger A. Goetsch
Norman S. Marks
Global Drug Surveillance: The WHO Programme 161(24)
for International Drug Monitoring
I. Ralph Edwards
Sten Olsson
Marie Lindquist
Bruce Hugman
Case-Control Surveillance 185(18)
Lynn Rosenberg
Patricia F. Coogan
Julie R. Palmer
Prescription-Event Monitoring 203(14)
Saad A.W. Shakir
PART IIIb Automated Data Systems Available 217(130)
for Pharmacoepidemiology Studies
Overview of Automated Databases in 219(4)
Pharmacoepidemiology
Brian L. Strom
Group Health Cooperative 223(18)
Kathleen W. Saunders
Robert L. Davis
Andy Stergachis
Kaiser Permanente Medical Care Program 241(20)
Joe V. Selby
David H. Smith
Eric S. Johnson
Marsha A. Raebel
Gary D. Friedman
Bentson H. McFarland
The HMO Research Network 261(10)
K. Arnold Chan
Robert L. Davis
Margaret J. Gunter
Jerry H. Gurwitz
Lisa J. Herrinton
Winnie W. Nelson
Marsha A. Raebel
Douglas W. Roblin
David H. Smith
Richard Platt
UnitedHealth Group 271(10)
Deborah Shatin
Nigel S.B. Rawson
Andy Stergachis
Medicaid Databases 281(14)
Sean Hennessy
Jeffrey L. Carson
Wayne A. Ray
Brian L. Strom
Health Services Databases in Saskatchewan 295(16)
Winanne Downey
MaryRose Stang
Patricia Beck
William Osei
James L. Nichol
Automated Pharmacy Record Linkage in The 311(12)
Netherlands
Hubert G. Leufkens
John Urquhart
The Tayside Medicines Monitoring Unit (MEMO) 323(14)
Li Wei
John Parkinson
Thomas M. MacDonald
The UK General Practice Research Database 337(10)
Joel M. Gelfand
David J. Margolis
Hassy Dattani
PART IIIc Other Approaches to 347(28)
Pharmacoepidemiology Studies
Other Approaches to Pharmacoepidemiology 349(14)
Studies
Brian L. Strom
How Should One Perform Pharmacoepidemiology 363(12)
Studies? Choosing Among the Available
Alternatives
Brian L. Strom
PART IV SELECTED SPECIAL APPLICATIONS OF 375(180)
PHARMACOEPIDEMIOLOGY
National Medicinal Drug Policies: Their 377(14)
Relationship to Pharmacoepidemiology
Suzanne Hill
David A. Henry
Premarketing Applications of 391(10)
Pharmacoepidemiology
Harry A. Guess
Studies of Drug Utilization 401(18)
David Lee
Ulf Bergman
Evaluating and Improving Physician 419(20)
Prescribing
Sumit R. Majumdar
Helene Levens Lipton
Stephen B. Soumerai
Drug Utilization Review 439(16)
Sean Hennessy
Stephen B. Soumerai
Helene Levens Lipton
Brian L. Strom
Special Methodological Issues in 455(32)
Pharmacoepidemiology Studies of Vaccine
Safety
Robert T. Chen
Robert L. Davis
Philip H. Rhodes
Pharmacoepidemiologic Studies of Devices 487(14)
Roselie A. Bright
Studies of Drug-Induced Birth Defects 501(14)
Allen A. Mitchell
Pharmacoepidemiology and Risk Management 515(16)
David J. Graham
Andrew D. Mosholder
Kate Gelperin
Mark I. Avigan
The Use of Pharmacoepidemiology to Study 531(8)
Medication Errors
Rainu Kaushal
David W. Bates
Hospital Pharmacoepidemiology 539(16)
Brian L. Strom
Rita Schinnar
PART V SELECTED SPECIAL METHODOLOGIC ISSUES 555(276)
IN PHARMACOEPIDEMIOLOGY
Determining Causation from Case Reports 557(14)
Judith K. Jones
Molecular Pharmacoepidemiology 571(16)
Stephen E. Kimmel
Hubert G. Leufkens
Timothy R. Rebbeck
Bioethical Issues in Pharmacoepidemiologic 587(12)
Research
David Casarett
Jason Karlawish
Elizabeth Andrews
Arthur Caplan
The Use of Randomized Controlled Trials for 599(12)
Pharmacoepidemiology Studies
Samuel M. Lesko
Allen A. Mitchell
The Use of Pharmacoepidemiology to Study 611(18)
Beneficial Drug Effects
Brian L. Strom
late Kenneth L. Melmon
Pharmacoeconomics: Economic Evaluation of 629(24)
Pharmaceuticals
Kevin A. Schulman
Henry A. Glick
Daniel Polsky
Using Quality-of-Life Measurements in 653(12)
Pharmacoepidemiologic Research
Holger Schunemann
Gordon H. Guyatt
Roman Jaeschke
N-of-1 Randomized Clinical Trials in 665(16)
Pharmacoepidemiology
Gordon H. Guyatt
Roman Jaeschke
Robin Roberts
The Use of Meta-analysis in 681(28)
Pharmacoepidemiology
Jesse A. Berlin
Carin J. Kim
Validity of Pharmacoepidemiologic Drug and 709(58)
Diagnosis Data
Suzanne L. West
Brian L. Strom
Charles Poole
Variable Compliance and Persistence with 767(24)
Prescribed Drug Dosing Regimens:
Implications for Benefits, Risks, and
Economics of Pharmacotherapy
John Urquhart
Bias and Confounding in Pharmacoepidemiology 791(20)
Ilona Csizmadi
Jean-Paul Collet
Jean-Francois Boivin
Novel Approaches to Pharmacoepidemiology 811(20)
Study Design and Statistical Analysis
Samy Suissa
PART VI CONCLUSION 831(10)
The Future of Pharmacoepidemiology 833(8)
Brian L. Strom
Sean Hennessy
Appendix A Sample Size Tables 841(18)
Appendix B Glossary 859(8)
Index 867